<span item_type="fundamental" item_id="3178d99216d5b39650ffad6303016b00" counter_id="ST/US/CINGW" env="prod"></span><span item_type="announcement" item_id="582316060736686465" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 0.</p><p></p><h3>Cash and Working Capital</h3><p>As of September 30, 2025, Cingulate Inc. had approximately $6.1 million in cash and cash equivalents, a decrease of $6.1 million from December 31, 2024. The company expects its cash will satisfy its capital needs into the second quarter of 2026 under the current business plan. Cingulate had approximately $1.6 million in working capital, a decrease of $6.1 million compared to $7.7 million as of December 31, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1862150/000149315225022132/ex99-1.htm"></span></p><h3>R&amp;D Expenses</h3><p>Research and development expenses were $2.8 million for the three months ended September 30, 2025, an increase of $1.4 million or 99.5% from the same period in 2024. This increase was due to higher personnel expenses, manufacturing costs, and regulatory costs.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1862150/000149315225022132/ex99-1.htm"></span></p><h3>G&amp;A Expenses</h3><p>General and administrative expenses were $3.1 million for the three months ended September 30, 2025, an increase of $1.3 million or 69.7% from the same period in 2024. The increase was primarily due to higher personnel expenses and commercial costs in preparation for a potential mid-2026 launch of CTx-1301.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1862150/000149315225022132/ex99-1.htm"></span></p><h3>Net Loss</h3><p>Net loss was $7.3 million for the three months ended September 30, 2025, compared to $4.1 million for the same period in 2024. The increase in net loss was primarily due to increased research and development costs and G&amp;A expenses.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1862150/000149315225022132/ex99-1.htm"></span></p><h3>Outlook / Guidance</h3><p>Cingulate Inc. anticipates needing approximately $7.0 million of additional capital to advance commercialization efforts through the May 31, 2026 PDUFA date for CTx-1301. The company remains focused on disciplined execution, operational efficiency, and creating long-term value for shareholders.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1862150/000149315225022132/ex99-1.htm"></span></p>

CINGULATE INC C/WTS 10/12/2026 (TO PUR COM) | 8-K: FY2025 Q3 Revenue: USD 0